Since its introduction in 1948, corticosteroids (CS) have played a significant role in the treatment of allergic and immunological disorders such as asthma, giant cell arteritis, systemic lupus erythematosus, rheumatoid arthritis and inflammatory bowel disease (IBD). However, its use is primarily limited by the potential serious adverse effects, which can be systemic or neuropsychiatric ([@CIT0001]). Current guidelines, therefore, recommend only short courses of CS in the treatment of acute IBD flares, with emphasis on CS-sparing maintenance therapy ([@CIT0006], [@CIT0007]).

While much attention has been paid to the systemic effects, relatively little is known about the neuropsychiatric effects that encompass a wide range of manifestations, most common of which include hypomania, depression and psychosis ([@CIT0008]). Although previous studies have attempted to define the incidence of CS-induced mood changes (CIMC), most of the studies assessed either non-IBD conditions, which may have different baseline susceptibilities ([@CIT0009]), or pediatric IBD patients ([@CIT0019], [@CIT0020]). Having a clear understanding of the neuropsychiatric adverse events will facilitate communication with patients and identification of such events more promptly, which is particularly important given that up to one-third of IBD patients may be nonadherent because of adverse medication effects ([@CIT0021]). Education and early recognition may encourage dialogue between care providers and patients and prevent patients from simply discontinuing therapy. In the current study, we aimed to determine the rate of CIMC in patients with IBD undergoing outpatient oral CS therapy.

METHODS {#s5}
=======

Study Design and Patient Population {#s6}
-----------------------------------

This is a prospective observational study at an outpatient clinic affiliated with an academic tertiary care centre (St. Paul's Hospital, University of British Columbia, Vancouver, Canada). Adult patients (age ≥19 as per provincial definition) with inflammatory bowel disease, diagnosed on endoscopy and/or imaging, who were undergoing outpatient oral prednisone therapy for acute flares of IBD between October 2013 and April 2016 were considered for inclusion. Exclusion criteria included hospitalization for management of IBD within 2 weeks prior to study entry (due to possible use of intravenous CS), liver cirrhosis (due to potential effect on CS metabolism), use of medications that interfere with CS metabolism (e.g., clarithromycin, cyclosporine, ritonavir and ketoconazole), change in psychiatric medication within one month of study entry, and active recreational drug use or alcohol abuse.

Proposed CS course consisted of prednisone 40 mg daily for two weeks ([@CIT0006], [@CIT0022]), followed by a tapering course of 5 mg/day reduction every week. The treatment course could be adjusted at the physician's discretion based on the subject's clinical condition.

Participants completed two validated questionnaires for mood assessment at the time of CS initiation (first visit), at two-week follow-up after initiation of CS therapy (second visit), and at the end of the CS taper (third visit). Disease activity was also monitored at each visit using Harvey-Bradshaw Index (HBI) and Simple Clinical Colitis Activity Index (SCCAI) for Crohn's disease and ulcerative colitis, respectively, by a physician, nurse or trained research assistant.

This study was approved by the institutional research ethics board and registered on clinicaltrials.gov (NCT01981889).

Questionnaire {#s7}
-------------

Participants' mood states were assessed at each visit using self-administered questionnaires that were validated in patients with various psychiatric disorders in the outpatient setting. Depressive symptoms were assessed using the Beck Depression Inventory II (BDI-II), a 21-item multiple choice questionnaire that asks participants to rate their symptoms such as sadness, loss of interest, guilt, agitation, suicidality, concentration and fatigue within the past two weeks ([@CIT0025]). The total BDI-II possible score was 63. Hypomanic and manic symptoms were assessed using the Activation subscale of the Internal State Scale version 2 (AS-ISSv2), which consists of five questions that ask participants to rate the degree of manic symptoms such as impulsivity, rapid thought process, over-activity and restlessness over the past 24 hours ([@CIT0026]). The total AS-ISSv2 score was 500, and a score of ≥155 was suggestive of mood elevation in the range of hypomania or mania and mixed state as seen in bipolar disorder. Of note is that hypomania and mania cannot be distinguished by this scoring system.

Mood changes were defined, a priori, as BDI-II increase by ≥10 and/or AS-ISSv2 increase by ≥50 between the first and second visit (i.e., after two weeks of prednisone). A change in BDI-II of 10 was chosen, as this increment also defines the various levels of depression severity. An AS-ISSv2 change of 50 was chosen because this is the minimum change required to appreciate symptom escalation in all five questions of this subscale and is also the amount previously observed in other studies with non-IBD conditions ([@CIT0013], [@CIT0027]).

Statistical Analysis {#s8}
--------------------

Our primary objective was to determine the rate of CIMC. A sample size calculation was performed based on an anticipated 40% rate of CS-induced mood change in IBD patients, based on previously published studies primarily focused on other immunological conditions ([@CIT0013], [@CIT0028], [@CIT0029]) using a 95% confidence interval with precision of 0.15 and an anticipated drop out rate of 20%. The original target sample size was 50. However, given that a higher than expected drop out rate of \~33% after the initial 15 subjects, an updated sample size of 66 was calculated based on an estimated 40% drop out rate.

Baseline characteristics that are continuous variables were summarized as mean and standard deviation or median and quartiles, while categorical variables were reported as frequency and percentage. Comparisons between subjects were conducted using Chi-square test, Fisher exact test, t-test and Wilcoxon rank sum test, as appropriate, to identify potential risk factors. Univariate analysis was performed for participants who developed mood changes by the second visit. Multivariate logistic regression was performed for variables with P\<0.20 in the univariate analysis. Correlations between mood score changes and IBD activity score changes were assessed using Spearman rank correlation coefficient. Pretreatment mood scores (baseline) and IBD activities were compared to those at follow-up visits using Wilcoxon signed-rank test.

Statistical analyses were performed using SAS 9.3 (SAS Institute Inc., Cary, NC, USA). Statistical significance was defined as P value less than 0.05.

RESULTS {#s9}
=======

During the study period, 66 patients were considered for inclusion. Thirteen subjects were excluded ([Figure 1](#F1){ref-type="fig"}). There was no significant difference in baseline characteristics ([Table 1](#T1){ref-type="table"}) between IBD patients who were excluded (n=13) compared with those who were included (n=53).

###### 

Baseline characteristics

  Variable                                    **Included (n**=**53**)   **Excluded (n**=**13**)   P
  ------------------------------------------- ------------------------- ------------------------- -------
  Age                                                                                             0.285
   Mean (SD)                                  40.0 (15.0)               45.1 (16.7)               
   Median (IQR)                               36.0 (26.0, 56.0)         48.0 (29.0, 57.0)         
   Range                                      (21.0, 68.0)              (22.0, 70.0)              
  Gender, n (%)                                                                                   0.420
   Female                                     26 (49.1)                 8 (61.5)                  
   Male                                       27 (50.9)                 5 (38.5)                  
  Diagnosis, n (%)\*                                                                              0.729
  Ulcerative colitis                          38 (71.7)                 8 (66.7)                  
  Crohn's disease                             15 (28.3)                 4 (33.3)                  
  Presence of psychiatric condition, n (%)†                                                       1.000
   None                                       48 (90.6)                 9 (90.0)                  
   Depression                                 4 (7.5)                   1 (10.0)                  
   Anxiety                                    1 (1.9)                   0 (0.0)                   
  Prior steroid exposure, n (%)†                                                                  0.393
   No                                         24 (45.3)                 6 (60.0)                  
   Yes                                        29 (54.7)                 4 (40.0)                  
  IBD maintenance therapy, n (%)†                                                                 
   None                                       7 (13.2)                  2 (10.0)                  0.573
   5ASA                                       33 (62.3)                 5 (50.0)                  0.467
   Immunomodulator                            7 (13.2)                  0 (0.0)                   0.223
   Biologic                                   12 (22.6)                 2 (20.0)                  0.854
   Topical steroid                            4 (7.5)                   1 (10.0)                  1.000
  First visit SCCAI                                                                               0.321
   Median (IQR)                               9.0 (8.0, 11.8)           9.0 (6.3, 10.0)           
   Mean (SD)                                  9.2 (2.7)                 7.6 (3.1)                 
   Range                                      (3.0, 14.0)               (2.0, 10.0)               
  First visit HBI‡                                                                                0.203
   Median (IQR)                               8.0 (5.5, 14.0)           5.0 (4.5, 5.5)            
   Mean (SD)                                  9.9 (6.2)                 5.0 (1.4)                 
   Range                                      (2.0, 22.0)               (4.0, 6.0)                
  First visit BDI-II§                                                                             0.881
   Median (IQR)                               9.0 (5.0, 13.0)           11.0 (7.0, 12.0)          
   Mean (SD)                                  10.2 (7.3)                12.1 (11.5)               
   Range                                      (0.0, 25.0)               (2.0, 41.0)               
  First visit AS-ISSv2¶                                                                           0.541
   Median (IQR)                               50.0 (0.0, 140.0)         40.0 (0.0, 102.5)         
   Mean (SD)                                  79.6 (86.4)               64.0 (78.3)               
   Range                                      (0.0, 300.0)              (0.0, 200.0)              

5ASA, 5-aminosalicylic acid

\*1 excluded patient with non-IBD diagnosis

†Data not available for three excluded patients

‡Data not available for two excluded patients

§Data not available for four excluded patients

¶Data not available for three excluded patients

![Enrollment flow chart.](gwy02301){#F1}

Of the 53 subjects included in analyses, two subjects required hospitalization during the study period for escalation of therapy, including intravenous CS and surgery. Five subjects did not complete the third-visit questionnaire. Median follow-up time of those included in analyses was 64 (range 7--125, interquartile range \[IQR\] 57--72) days since start of prednisone therapy.

Thirty-three (62%) subjects completed the prednisone course per protocol. Seven subjects had prolonged taper due to persistent clinical symptoms, while 15 had rapid taper (one by physician during therapy due to insomnia; one by physician during therapy due to hypomania, which was also captured by AS-ISSv2; one by physician during therapy due to surgical cure obviating need for CS; one by physician during therapy due to poor response prompting therapy switch; four by physician during therapy due to exceptional response making longer therapy unnecessary; one by physician at initiation of therapy due to history of mood change; four by physician at initiation of therapy; two without specified reason).

Rate of Corticosteroid-Induced Mood Changes {#s10}
-------------------------------------------

Overall, the rate of mood changes with oral prednisone therapy was 49.1% (26 of 53) after a median of 15 (range 7--32, IQR 7--32) days on prednisone; the majority of the cases (25 of 26) were secondary to increases in manic symptoms as measured by AS-ISSv2, of which four also had concomitant depressive symptoms.

There was a significant increase in the AS-ISSv2 score with prednisone therapy at the second visit (mean 79.6 ± 86.4 versus 135.5 ± 120.2, P=0.004), which later returned to pretreatment level following the completion of tapering course at the third visit (mean 79.6 ± 86.4 versus 60.4 ± 72.5, P=0.250). However, no significant change in the BDI-II was seen between initial and subsequent visits. ([Figure 2](#F2){ref-type="fig"})
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Clinical Disease Activities {#s11}
---------------------------

Participants' IBD symptoms improved with CS therapy both during and after completion of prednisone therapy. SCCAI improved from mean of 9.2 ± 2.7 to 2.7 ± 2.0 (P\<0.001), and HBI improved from mean of 9.9 ± 6.2 to 6.4 ± 4.5 (P=0.024) at third visit after completion of CS treatment.

Risk Factors and Disease Activity Association {#s12}
---------------------------------------------

In the univariate analysis, younger age (32.8 versus 46.9 years) and female gender (65.4% versus 33.3%) were found to be associated with significant AS-ISSv2 or BDI-II changes, while IBD diagnosis, presence of psychiatric condition, type of maintenance therapy, initial disease activity score, duration of prednisone before mood reassessment, and positive response to treatment (defined as HBI/SCCAI reduction from ≥5 in first visit to \<5 in second visit) were not. ([Table 2](#T2){ref-type="table"}) In the multivariate analysis, only younger age remained an independent risk factor (every five-year decrease, odds ration \[OR\] 1.41) ([Table 3](#T3){ref-type="table"}).

###### 

Univariate analysis of factors associated with mood score changes

  Variable                                   BDI-II increase by ≥10 and/or AS-ISSv2 increase by ≥50                       
  ------------------------------------------ -------------------------------------------------------- ------------------- ---------
  Age                                                                                                                     \<0.001
   Mean (SD)                                 46.9 (15.2)                                              32.8 (11.1)         
   Median (IQR)                              52.0 (33.0, 61.0)                                        30.5 (24.0, 38.0)   
   Range                                     (21.0, 68.0)                                             (21.0, 65.0)        
  Female, n (%)                              9 (33.3)                                                 17 (65.4)           0.020
  Diagnosis, n (%)                                                                                                        0.317
   Ulcerative colitis                        21 (77.8)                                                17 (65.4)           
   Crohn's                                   6 (22.2)                                                 9 (34.6)            
  Presence of psychiatric condition, n (%)                                                                                0.610
   None                                      24 (88.9)                                                24 (92.3)           
   Depression                                3 (11.1)                                                 1 (3.8)             
   Anxiety                                   0 (0.0)                                                  1 (3.8)             
  Prior Steroid exposure, n (%)              13 (48.1)                                                16 (61.5)           0.328
  IBD maintenance therapy, n (%)                                                                                          
   None                                      2 (7.4)                                                  5 (19.2)            0.250
   5ASA                                      20 (74.1)                                                13 (50.0)           0.071
   Immunomodulator                           3 (11.1)                                                 4 (15.4)            0.704
   Biologic                                  6 (22.2)                                                 6 (23.1)            0.941
   Topical steroid                           2 (7.4)                                                  2 (7.7)             1.000
  First visit SCCAI                                                                                                       0.280
   Median (IQR)                              9.0 (7.0, 11.0)                                          9.0 (8.0, 12.0)     
   Mean (SD)                                 8.7 (3.0)                                                9.8 (2.3)           
   Range                                     (3.0, 14.0)                                              (6.0, 13.0)         
  First visit HBI                                                                                                         0.636
   Median (IQR)                              10.5 (5.0, 15.0)                                         7.0 (6.0, 10.0)     
   Mean (SD)                                 10.8 (6.2)                                               9.2 (6.4)           
   Range                                     (4.0, 20.0)                                              (2.0, 22.0)         
  Positive response to treatment, n (%)                                                                                   0.771
   No                                        13 (54.2)                                                14 (58.3)           
   Yes                                       11 (45.8)                                                10 (41.7)           
  No. of days between 1st and 2nd visit                                                                                   0.551
   Median (IQR)                              14.0 (14.0, 17.0)                                        15.0 (14.0, 16.0)   
   Mean (SD)                                 15.3 (4.4)                                               16.0 (3.5)          
   Range                                     (7.0, 32.0)                                              (12.0, 27.0)        
  Therapy protocol deviation, n (%)                                                                                       0.306
   Shorter                                   10 (37.0)                                                5 (19.2)            
   Longer                                    13 (48.1)                                                18 (69.2)           
   Per protocol                              4 (14.8)                                                 3 (11.5)            

5ASA, 5-aminosalicylic acid

###### 

Multivariate analysis of factors associated with mood score changes.

                              BDI-II increase by ≥10 and/or AS-ISSv2 increase by ≥50   
  --------------------------- -------------------------------------------------------- -------
  Age (per 5-year decrease)   1.41 (1.09, 1.82)                                        0.010
  Male                        0.44 (0.12, 1.69)                                        0.233
  Use of 5ASA                 0.32 (0.08, 1.21)                                        0.093

5ASA, 5-aminosalicylic acid

Both initial assessment of SCCAI and HBI were found to have weak to moderate correlation with BDI-II (Spearman correlation of 0.37 \[P=0.022\] and 0.59 \[P=0.020\], respectively) but not with AS-ISSv2 at the initial visit prior to prednisone therapy. However, the correlation between IBD disease activity and BDI-II disappears during and after prednisone therapy (i.e., at second and third visits). There was also no significant correlation between the changes in the IBD disease activities and the changes in the mood symptoms between first and second visits.

DISCUSSION {#s13}
==========

This is the first prospective study to formally assess CS-induced mood changes in adult patients with IBD using self-administered scoring systems that have been validated in general population with various psychiatric condition ([@CIT0025], [@CIT0030]). To the best of our knowledge, there is no evidence directly linking CIMC to treatment nonadherence or poor outcomes in IBD patients, but medication adverse events and psychological distress are associated with compromised adherence to therapy in IBD patients ([@CIT0021], [@CIT0030]). In addition, mood disturbances (e.g., depression, mania and hypomania) are associated with reduced quality of life in patients with bipolar disorder ([@CIT0031]) and so is CIMC in pediatric oncology patients and their families ([@CIT0032]). A better understanding of CIMC is therefore needed to allow healthcare providers and patients to better prepare for such an adverse event and minimize its impact.

The rate of 49.1% is consistent with the results from previous studies. For example, psychological and behavioural disturbances among IBD patients were observed at a rate of 65 events per 100 patient-years in a meta-analysis by Hoes et al., which included studies employing various types of CS and dichotomous adverse event outcomes ([@CIT0009]). In a randomized controlled trial comparing different prednisolone formulations, Rhodes et al. reported 42% incidence of mood changes after two weeks of prednisolone ([@CIT0033]). However, the incidence was defined based on patients' perception of presence or absence of mood change instead of more formal assessment tools.

Previous reports demonstrated that hypomania and frank mania tend to occur more frequently than depressive symptoms in acute CS therapy for non-IBD conditions ([@CIT0012], [@CIT0034]). Similarly, symptoms of (hypo)mania (i.e., impulsivity, rapid thought process, overactivity, feeling "sped up" inside or restlessness) were the primary psychological or behavioural changes in this study population. Twelve participants (22.6%) developed new onset mood features in the range of hypomania or mania and mixed state of bipolar disorder (i.e., AS-ISSv2 ≥155) at the second visit ([@CIT0026]), of whom eight had complete resolution at the third visit. It was not possible to pinpoint the onset of the changes given the study design, but previous studies demonstrated CIMC in as early as three days of therapy when at least a 40 mg equivalent of prednisone was used ([@CIT0013], [@CIT0014]). The clinical implication is less clear for the 13 patients who experienced increases in AS-ISSv2 by at least 50 points but did not meet cutoff for hypomania, mania or mixed state. Nonetheless, this detectable change likely remains clinically relevant and is an outcome of interest in this observational study.

It is worth noting in this study that mood changes simply reversed with tapering course of CS and did not require additional intervention such as psychotropic medications, which have been reported in the past ([@CIT0035]). None of the subjects required hospitalization for the management of psychological symptoms.

Over one-third of the participants' CS course deviated from the protocol, but the majority was guided by clinical response to therapy. Three subjects' courses were shortened due to intolerance (hypomania, insomnia and history of mood change), while no clinical rationale was provided in six (including four whose shorter courses were determined at initiation). The person with a history of CIMC did develop symptoms consistent with hypomania or mania (i.e., AS-ISSv2 ≥155) during treatment but returned to pretreatment state at the end of the study. Given that the protocol deviations were primarily guided by clinical symptoms, they were understandably not associated with detectable psychological changes on the questionnaires.

The mood changes observed in this study appeared largely independent of the IBD activity, as was observed in obstructive airway diseases ([@CIT0013], [@CIT0018]). This is demonstrated by the return of the mood state to pretreatment level while clinical IBD activity remained stable or improved following completion of therapy. In addition, there was no correlation between the changes in clinical IBD activities and the changes in mood scores, which supports prednisone's role in the mood score changes. It is also worth noting that neither clinical disease activity indices incorporated objective measures such as endoscopic assessment or biomarkers, but SCCAI was previously demonstrated to correlate well with endoscopic inflammation, as well as serum and fecal inflammatory markers ([@CIT0036]). The Harvey-Bradshaw Index was chosen for its straightforward administration and good correlation with Crohn's Disease Activity index, which has been utilized extensively in previous Crohn's disease trials ([@CIT0037]). Although HBI does not correlate well with endoscopic inflammation or fecal inflammatory marker ([@CIT0036], [@CIT0038]), use of such clinical disease activity index is warranted in absence of an objective modality that can accurately assess all phenotypes of Crohn's disease.

Patients with psychiatric comorbidities only accounted for 9% (five of 53) of the study population, and all were taking stable doses of psychiatric medications. Only two of five developed detectable mood changes, which is comparable to the rest of the study population, but the numbers are too small to draw any meaningful conclusion. We did not include patients who had recent change in psychiatric medications to minimize the impact of their underlying mental illness.

Female gender and younger age were associated with mood changes in the univariate analysis, but only age remained statistically significant in the multivariate analysis. Naber et al. reported that gender is not a risk factor for "neuropsychological and psychopathological changes" in patients receiving high-dose CS for ocular conditions ([@CIT0014]). In contrast, higher incidence of CIMC in females was observed in earlier studies, but the interpretation was confounded by female predominance in certain autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus ([@CIT0028], [@CIT0039], [@CIT0040]).

Similar finding of emotional function impairment was observed in pediatric IBD patients treated with CS, compared with controls (IBD in remission) not taking CS ([@CIT0020]). However, there is paucity of data on the relationship between age and risk of CIMC in the literature. Younger age has emerged as an independent risk factor for CIMC in our study, contrary to a previous report by Lewis and Smith examining psychiatric disturbances in a variety of conditions requiring CS for immunosuppression ([@CIT0028]) and contrary to a prospective study by Brown et al. assessing mood changes during prednisone treatment of asthma ([@CIT0013]). To our knowledge, there is no data directly comparing pediatric to adult population in terms of susceptibility to CIMC, but an earlier study found greater impact of CS on behaviour and mood in preschool children with acute lymphoblastic leukemia compared with school-aged children ([@CIT0041]). It was postulated that the developing brain may be more susceptible to CS adverse effect ([@CIT0020]), but this hypothesis is not applicable to adult patients. It is possible that the observed association was related to the greater proportion of younger patients with IBD in this study, compared with other autoimmune conditions included in previous reports. Alternatively, it may be related to a different phenotype of the disease in younger patients. Larger prospective data is required to draw more definitive conclusions regarding female gender and younger age as risk factors for CIMC among IBD patients.

This study has several limitations, including the single-centre design and the lack of a control group. However, as CS use is the standard of care in patients with IBD flares, ethical considerations preclude the institution of a placebo-controlled group. Comparison with an alternate induction agent such as anti-tumor necrosis factor alpha was also not feasible, as many patients were on concomitant CS or immunomodulator at the time of anti-tumor necrosis factor alpha initiation. To address this deficit, we incorporated a follow-up visit at the end of the CS treatment as internal control and demonstrated that the mood state returned to pretreatment level after completion of therapy. A potential confounder is patient adherence to prednisone therapy. As the first step to demonstrate the rate of CIMC in a real-life experience, patient adherence was not monitored; however, this information could be vital in future studies as an endpoint since nonadherence may be a result of CIMC.

The relatively small sample size limited the precision in assessing the rate of CIMC but did so without sacrificing accuracy. A larger sample size would have required a substantial, prohibitive amount of resources for recruitment. Therefore, we calculated the sample size based on a precision of 0.15. This study's results are not generalizable to inpatients with IBD flares, which represent a significant portion of patients requiring systemic CS therapy at our centre. Inpatients were excluded to avoid potentially confounding effects of their severe disease activity and comorbidities, such as malnutrition and infection, on psychological state ([@CIT0042]). Similarly, recent psychiatric medication changes and active alcohol or recreational drug use were excluded to minimize confounding. Further prospective study with larger sample size is needed to clarify the effect of CS on mood in these subgroups.

In conclusion, CS treatment was associated with frequent mood changes, affecting nearly half of the subjects in this study. The most common manifestation was mood elevation during therapy, but subsequently the affective state returned to pretreatment level upon completion of therapy without relapse of clinical disease activity. Healthcare providers should inform patients of such a risk and monitor for need of intervention. Future studies may help to clarify the role for concomitant therapy to ameliorate the mood-related side effects for patients requiring CS for management of their IBD.
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